PARP10

Across TCGA pan-cancer cohorts, PARP10 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PARP10 data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PARP10 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PARP10 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where PARP10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.979	0.163	.003	18	view →
LUAD	OS	Median	II,III,IV	0.911	0.434	.010	9	view →
HNSC	DFS	Quartile	IV	0.781	0.400	.015	8	view →
PDAC	OS	Median	III,IV	0.505	0.973	.003	7	view →
GBM	DFS	Tertile	All	0.657	0.860	.016	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PARP10–CCRCC (DFS)

Open the CCRCC breakdown →